2 Minute Medicine Rewind February 12, 2024
Effect of Tai Chi vs Aerobic Exercise on Blood Pressure in Patients With Prehypertension: A Randomized Clinical Trial 1. This ...
Tag: cognitive decline
Gantenerumab does not slow cognitive decline in early Alzheimer’s
1. In these two randomized parallel-group trials, the use of gantenerumab did not lead to slower cognitive decline over 116 ...
#VisualAbstract: Two Phase 3 Trials of Gantenerumab in Early Alzheimer’s Disease
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be ...
#VisualAbstract: Trial of Solanezumab in Preclinical Alzheimer’s Disease
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Retinal optical coherence tomography (OCT) measurements may be associated with genetic Alzheimer’s disease risk
1. In a retrospective study examining 50,000 optical coherence tomography (OCT) images from a large database, thicknesses of several different ...
#VisualAbstract: Lecanemab reduced cognitive and functional decline in early Alzheimer’s disease compared to placebo
1. Lecanemab was associated with reduced amyloid markers in early Alzheimer’s disease as compared to placebo. 2. Lecanemab also resulted ...
Decline in gait speed paired with domain-specific cognition decline may be a useful screening assessment for dementia
1. A decline in gait speed paired with domain-specific cognitive decline proved to be strongly correlated with subsequent development of ...
Thyroid dysfunction not associated with cognitive decline
1. This retrospective, multicohort study demonstrated no cross-sectional or longitudinal associations between thyroid dysfunction and global cognition, memory, executive function, ...
Verubecestat linked to worse outcomes among patients with prodromal Alzheimer’s Disease compared to placebo
1. Verubecestat, an orally administered beta amyloid precursor protein-cleaving enzyme 1 (BACE-1) inhibitor , did not slow or prevent the progression ...
Solanezumab does not change cognitive decline in mild Alzheimer’s disease
1. In patients with mild Alzheimer’s disease solanezumab, an antibody designed to facilitate clearance of amyloid-beta plaques, did not significantly ...